[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-281318-105":3,"detail-sidebar-cat-1-en-105":85,"doc-detail-281318-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","benlysta-sample-letter-of-appeal","BENLYSTA - Sample Letter of Appeal","","A template appeal letter supporting coverage reconsideration for BENLYSTA (belimumab) when a health insurance plan denies treatment coverage. The letter provides customizable patient, claim, and diagnosis fields, and explains the drug’s mechanism of action through BLyS-specific inhibition relevant to SLE and autoimmune disease activity. It outlines patient history, prior therapies, medical necessity rationale, and a request for prompt access and adequate coverage, including suggested enclosures and contact for follow-up.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/letters/","Letters",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/benlysta-sample-letter-of-appeal/281318/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/benlysta-sample-letter-of-appeal/281318.png","ImageObject",442,249,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-16",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Who can submit the BENLYSTA appeal, and on whose behalf?","Question",{"text":63,"@type":64},"A patient’s health insurance/payer can deny coverage, and the decision can be appealed by a provider on behalf of the patient.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What information does the letter template request for the appeal?",{"text":68,"@type":64},"It collects date, payer details, claim reference (HCPCS code and drug/billing unit), patient name, group/policy number, dates of service, and diagnosis (code and description), plus patient clinical history.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the letter explain why BENLYSTA may be medically necessary?",{"text":72,"@type":64},"It describes BENLYSTA as a BLyS-specific inhibitor that binds and inhibits BLyS activity, discusses BLyS’s role in B-cell survival and autoantibody production, and notes evidence linking BLyS inhibition to reduced SLE disease activity.",{"name":74,"@type":61,"acceptedAnswer":75},"What documents are suggested as enclosures for the appeal?",{"text":76,"@type":64},"Suggested enclosures include medical records and clinical notes/labs, denial documentation, relevant FDA approval letter information, prescribing information (with the IFU reference), and important safety information.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},281318,1791397856,{"code":4,"msg":86,"data":87},"success",[88,93,98,103,108,113,118,122,127],{"id":89,"doc_module":22,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},11,"Presentations",90,"presentations",{"id":94,"doc_module":22,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},12,"Resumes",80,"resumes",{"id":99,"doc_module":22,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},14,"Invoices",70,"invoices",{"id":104,"doc_module":22,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},15,"Posters",60,"posters",{"id":109,"doc_module":22,"doc_module_name":25,"category_name":110,"show_sort_weight":111,"slug":112},16,"Social Media",50,"social-media",{"id":114,"doc_module":22,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},17,"Forms",40,"forms",{"id":119,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":120,"slug":121},18,30,"letters",{"id":123,"doc_module":22,"doc_module_name":25,"category_name":124,"show_sort_weight":125,"slug":126},21,"Paper Templates",5,"papers-templates",{"id":128,"doc_module":22,"doc_module_name":25,"category_name":129,"show_sort_weight":4,"slug":130},158,"General","general-158",{"code":4,"msg":86,"data":132},{"doc_id":83,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":22,"category_id":119,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":22},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","A patient's health insurance/payer may deny a patient request for coverage for treatment with BENLYSTA (belimumab) . The decision can be appealed by a provider on behalf of the patient. When submitting an appeal to a patient’s health insurance plan/payer, the provider can help explain the rationale and clinical decision-making behind the choice of a specific therapy.  \nThe following is a template letter of appeal for BENLYSTA that can be customized based on your patient’s medical history and demographic information.  \nSAMPLE LETTER OF APPEAL  \n[Date]  \n[Plan/Payer Name][Payer Street Address][Payer City, State Zip Code]  \nRe: Appeal Letter for [HCPCS Code] [Drug Name, Billing Unit]  \nPatient: [Patient Full Name]  \nGroup/Policy Number: [Patient Group and Policy Number] Date(s) of Service: [Date(s)]  \nDiagnosis: [Code & Description]  \nDear [Name or Contact]:  \nThis letter serves as a formal appeal for reconsideration of a claim for BENLYSTA (belimumab), which was provided to [patient name] on [date of service] . [Patient Name] has been under treatment for [diagnosis] since [date of onset] . [Insurance company name] has stated that BENLYSTA is not covered because [reason for denial] .  \nTreatment Information  \nBENLYSTA (belimumab) is a human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS.  \nBENLYSTA inhibits the biological activity of B-lymphocyte stimulator, or BLyS. BLyS is a naturally occurring protein discovered by HGS, which is required for the survival and development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body’s first line of defense against infection. In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues. The results of prospective observational studies show a significant correlation of elevated levels of BLyS with SLE disease activity.  \nBENLYSTA acts by: (1) specifically recognizing and binding to BLyS,(2) inhibiting BLyS’s stimulation of B-cell development, and (3) restoring the potential for autoantibody-producing B cells to undergo the normal process of apoptosis (programmed cell death) . Preclinical and clinical studies show that BLyS antagonists such as BENLYSTA can reduce autoantibody levels in SLE. The results of three pivotal Phase 3 trials show that belimumab can reduce SLE disease activity.  \nPatient History and Diagnosis  \n[Patient Name] is a [age]-year-old [male/female] who has been under treatment for [diagnosis] since [date] . During this time,[Patient] has been treated with other therapies including [discuss previous therapies and patient’s response to therapy] . [Continue with patient history and clinical support for medical necessity] .  \nI believe it is imperative that this patient was ensured immediate access to BENLYSTA. Subsequently, it is crucial that [insurance company name] provide adequate coverage for BENLYSTA for this patient in the spirit of providing the best medical treatment available for [diagnosis] .  \nOn behalf of [Patient Name], we would appreciate your reconsideration of the claim for BENLYSTA dated [date of claim] . Please call me at [physician phone number] if I can be of further assistance or you require additional information.  \nSincerely,  \n[Physician’s Name], [Degree Initials][Physician’s Practice Name]  \nSuggested Enclosures:  \n• Medical records and clinical notes & labs  \n• Denial documentation (from the patient's health insurance/payer)  \n• FDA approval letter available at:  \n[https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=N&ai=0](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=browseByLetter.page&productLetter=N&ai=0)  \n• Prescribing Information (PI) -please also visit  \n[https:/","cbCainJ0JkVucjF0","https://ap.wps.com/l/cbCainJ0JkVucjF0","pdf",161404,"English","# SAMPLE LETTER OF APPEAL\n## Treatment Information\n## Patient History and Diagnosis\n## Suggested Enclosures","[{\"question\":\"Who can submit the BENLYSTA appeal, and on whose behalf?\",\"answer\":\"A patient’s health insurance/payer can deny coverage, and the decision can be appealed by a provider on behalf of the patient.\"},{\"question\":\"What information does the letter template request for the appeal?\",\"answer\":\"It collects date, payer details, claim reference (HCPCS code and drug/billing unit), patient name, group/policy number, dates of service, and diagnosis (code and description), plus patient clinical history.\"},{\"question\":\"How does the letter explain why BENLYSTA may be medically necessary?\",\"answer\":\"It describes BENLYSTA as a BLyS-specific inhibitor that binds and inhibits BLyS activity, discusses BLyS’s role in B-cell survival and autoantibody production, and notes evidence linking BLyS inhibition to reduced SLE disease activity.\"},{\"question\":\"What documents are suggested as enclosures for the appeal?\",\"answer\":\"Suggested enclosures include medical records and clinical notes/labs, denial documentation, relevant FDA approval letter information, prescribing information (with the IFU reference), and important safety information.\"}]","BENLYSTA - Sample Letter of Appeal | PDF",1789565472]